vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and VARONIS SYSTEMS INC (VRNS). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $173.1M, roughly 1.2× VARONIS SYSTEMS INC). On growth, VARONIS SYSTEMS INC posted the faster year-over-year revenue change (26.9% vs 11.1%). VARONIS SYSTEMS INC produced more free cash flow last quarter ($49.0M vs $38.4M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 15.2%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Varonis Systems, Inc. is a software company based in Miami, Florida with R&D offices in Herzliya, Israel. The company’s Data Security Platform analyzes data and data activity using the insights to identify data exposure risks stemming from access permissions and software-as-a-service (SaaS) app configurations, triggering automated remediation capabilities in response.

CORT vs VRNS — Head-to-Head

Bigger by revenue
CORT
CORT
1.2× larger
CORT
$202.1M
$173.1M
VRNS
Growing faster (revenue YoY)
VRNS
VRNS
+15.8% gap
VRNS
26.9%
11.1%
CORT
More free cash flow
VRNS
VRNS
$10.6M more FCF
VRNS
$49.0M
$38.4M
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
15.2%
VRNS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
VRNS
VRNS
Revenue
$202.1M
$173.1M
Net Profit
$24.3M
Gross Margin
98.7%
76.0%
Operating Margin
2.2%
-1.7%
Net Margin
12.0%
Revenue YoY
11.1%
26.9%
Net Profit YoY
-21.0%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
VRNS
VRNS
Q1 26
$173.1M
Q4 25
$202.1M
$173.4M
Q3 25
$207.6M
$161.6M
Q2 25
$194.4M
$152.2M
Q1 25
$157.2M
$136.4M
Q4 24
$181.9M
$158.5M
Q3 24
$182.5M
$148.1M
Q2 24
$163.8M
$130.3M
Net Profit
CORT
CORT
VRNS
VRNS
Q1 26
Q4 25
$24.3M
$-27.8M
Q3 25
$19.7M
$-29.9M
Q2 25
$35.1M
$-35.8M
Q1 25
$20.5M
$-35.8M
Q4 24
$30.7M
$-13.0M
Q3 24
$47.2M
$-18.3M
Q2 24
$35.5M
$-23.9M
Gross Margin
CORT
CORT
VRNS
VRNS
Q1 26
76.0%
Q4 25
98.7%
78.9%
Q3 25
97.8%
78.2%
Q2 25
98.2%
79.5%
Q1 25
98.5%
78.7%
Q4 24
98.4%
83.6%
Q3 24
98.4%
83.8%
Q2 24
98.5%
82.8%
Operating Margin
CORT
CORT
VRNS
VRNS
Q1 26
-1.7%
Q4 25
2.2%
-17.5%
Q3 25
4.9%
-22.2%
Q2 25
13.7%
-24.0%
Q1 25
2.2%
-32.1%
Q4 24
13.9%
-11.1%
Q3 24
25.5%
-16.0%
Q2 24
21.7%
-22.1%
Net Margin
CORT
CORT
VRNS
VRNS
Q1 26
Q4 25
12.0%
-16.0%
Q3 25
9.5%
-18.5%
Q2 25
18.1%
-23.5%
Q1 25
13.1%
-26.2%
Q4 24
16.9%
-8.2%
Q3 24
25.9%
-12.4%
Q2 24
21.7%
-18.4%
EPS (diluted)
CORT
CORT
VRNS
VRNS
Q1 26
Q4 25
$0.20
$-0.23
Q3 25
$0.16
$-0.26
Q2 25
$0.29
$-0.32
Q1 25
$0.17
$-0.32
Q4 24
$0.25
$-0.12
Q3 24
$0.41
$-0.16
Q2 24
$0.32
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
VRNS
VRNS
Cash + ST InvestmentsLiquidity on hand
$372.2M
$179.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$647.8M
$453.5M
Total Assets
$836.7M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
VRNS
VRNS
Q1 26
$179.3M
Q4 25
$372.2M
$883.7M
Q3 25
$421.7M
$671.3M
Q2 25
$342.2M
$770.9M
Q1 25
$322.8M
$567.6M
Q4 24
$383.3M
$529.0M
Q3 24
$380.3M
$844.8M
Q2 24
$473.2M
$582.5M
Stockholders' Equity
CORT
CORT
VRNS
VRNS
Q1 26
$453.5M
Q4 25
$647.8M
$598.7M
Q3 25
$631.9M
$604.8M
Q2 25
$635.8M
$341.5M
Q1 25
$683.3M
$367.7M
Q4 24
$679.6M
$455.7M
Q3 24
$638.8M
$428.6M
Q2 24
$596.2M
$458.6M
Total Assets
CORT
CORT
VRNS
VRNS
Q1 26
$1.6B
Q4 25
$836.7M
$1.8B
Q3 25
$823.6M
$1.7B
Q2 25
$801.7M
$1.6B
Q1 25
$846.5M
$1.6B
Q4 24
$840.6M
$1.7B
Q3 24
$784.3M
$1.5B
Q2 24
$714.6M
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
VRNS
VRNS
Operating Cash FlowLast quarter
$38.4M
$55.0M
Free Cash FlowOCF − Capex
$38.4M
$49.0M
FCF MarginFCF / Revenue
19.0%
28.3%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters
$118.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
VRNS
VRNS
Q1 26
$55.0M
Q4 25
$38.4M
$24.7M
Q3 25
$54.5M
$33.4M
Q2 25
$43.9M
$21.3M
Q1 25
$5.1M
$68.0M
Q4 24
$59.3M
$24.3M
Q3 24
$73.8M
$22.5M
Q2 24
$41.2M
$11.7M
Free Cash Flow
CORT
CORT
VRNS
VRNS
Q1 26
$49.0M
Q4 25
$38.4M
$20.7M
Q3 25
$30.4M
Q2 25
$43.9M
$18.0M
Q1 25
$5.0M
$65.7M
Q4 24
$59.2M
$19.9M
Q3 24
$72.2M
$21.3M
Q2 24
$40.8M
$10.9M
FCF Margin
CORT
CORT
VRNS
VRNS
Q1 26
28.3%
Q4 25
19.0%
12.0%
Q3 25
18.8%
Q2 25
22.6%
11.8%
Q1 25
3.2%
48.1%
Q4 24
32.5%
12.6%
Q3 24
39.5%
14.4%
Q2 24
24.9%
8.4%
Capex Intensity
CORT
CORT
VRNS
VRNS
Q1 26
Q4 25
0.0%
2.3%
Q3 25
0.0%
1.8%
Q2 25
0.0%
2.2%
Q1 25
0.1%
1.7%
Q4 24
0.1%
2.7%
Q3 24
0.9%
0.8%
Q2 24
0.3%
0.6%
Cash Conversion
CORT
CORT
VRNS
VRNS
Q1 26
Q4 25
1.58×
Q3 25
2.77×
Q2 25
1.25×
Q1 25
0.25×
Q4 24
1.93×
Q3 24
1.56×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

VRNS
VRNS

SaaS$161.1M93%
Term license subscriptions$6.9M4%
Maintenance and services$5.2M3%

Related Comparisons